|
Retrospective Studies
|
N05.715.360.330.500.750.825 |
|
|
Phenytoin
|
D03.383.129.308.432.555.730 |
|
|
Chemokine CCL21
|
D23.469.200.110.890 |
|
|
Integrin alphaXbeta2
|
D12.776.395.550.200.275 |
|
|
Factor X
|
D12.776.811.243.471 |
|
|
Oral Sprays
|
D26.255.165.055.527 |
|
|
Glycogen Storage Disease Type IIb
|
C16.320.565.202.449.510 |
|
|
Lysosomal Storage Diseases, Nervous System
|
C18.452.648.595.554 |
|
|
Lysosomal Storage Diseases
|
C18.452.648.595 |
|
|
Quantitative Structure-Activity Relationship
|
D021281 |
[A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds.
] |
|
Agatoxins
|
D060848 |
[A class of polyamine and peptide toxins which are isolated from the venom of spiders such as Agelenopsis aperta.
] |
|
Cell Engineering
|
D060846 |
[Methods and techniques used to modify or select cells and develop conditions for growing cells for biosynthetic production of molecules (METABOLIC ENGINEERING), for generation of tissue structures and organs in vitro (TISSUE ENGINEERING), or for other BIOENGINEERING research objectives.
] |
|
Interferon-gamma
|
D23.529.374.440.893 |
|
|
Carbonic Anhydrase IV
|
D12.776.395.550.448.160 |
|
|
Basic Reproduction Number
|
N01.224.935.597.080 |
|
|
Metabolic Engineering
|
D060847 |
[Methods and techniques used to genetically modify cells' biosynthetic product output and develop conditions for growing the cells as BIOREACTORS.
] |
|
Scleroplasty
|
E04.680.700 |
|
|
Hoarding
|
D060845 |
[A persistent difficulty discarding or parting with possessions.
] |
|
Excitatory Amino Acid Transporter 5
|
D12.776.157.530.937.250.500.968 |
|
|
TATA Box
|
G05.360.340.024.340.137.750.680.850 |
|
